Bordeaux (France), Castres (France), May 9th 2016 - Pierre Fabre Fund for Innovation, an Open Innovation initiative launched by Pierre Fabre Laboratories, and MATWIN, a nationwide program dedicated to identifying and supporting early oncology projects with a market potential, strengthen their collaboration ahead of the upcoming MEET2WIN Oncology Business Convention.
Created and hosted by MATWIN, the MEET2WIN Business Convention, which is entirely dedicated to open innovation and collaborative research in oncology, will be held on May 12th and 13th in Bordeaux, France. More than 200 participants involved in the oncology innovation cycle (large groups, biotech companies, startups, as well as project initiators, researchers and fundraisers) are expected to attend, meet and forge new collaborations.
A partner of MATWIN since 2014, the Pierre Fabre Group will expand its contribution to this year's MEET2WIN Convention. As such, several high potential research projects in oncology and onco-dermatology that have been pre-selected by MATWIN will be evaluated by the Pierre Fabre Fund for Innovation. If selected and a partnership signed, these projects will benefit from the support and expertise of the Pierre Fabre Group across the spectrum of R&D activites and/orfrom financial support for their project in order to advance through the clinic and to significant value inflexion points. The MEET2WIN Convention will offer project bearers, pre-selected by MATWIN, an opportunity to meet executives from Pierre Fabre Fund for Innovation and submit their applications directly to them.
"Biotech entrepreneurs in oncology and onco-dermatology can expect a highly collaborative interaction with us in order to advance projects in the most efficient manner across the product development steps.. This collaboration between MATWIN and Pierre Fabre Fund for Innovation falls into Pierre Fabre Pharmaceuticals' R&D strategy to forge partnerships with external parties showing a real potential for delivering highly differentiated medicines to patients," said Laurent Audoly, Head of R&D Pierre Fabre Pharmaceuticals and Managing Partner of the Pierre Fabre Fund for Innovation.
"We want to offer true flexibility to our partners, without forcing them to follow a set pattern. We are willing to take risks on projects that are still at a very early stage of the innovation process. The whole purpose of strengthening our ties with MATWIN is to identify projects of interest," said Vincent Serra, Operating Manager of the Pierre Fabre Fund for Innovation.
"This new partnership with Pierre Fabre Fund for Innovation offers additional opportunities for project applications to MATWIN. It will expand the expertise and support we provide at an early stage, allowing the most promising projects to boost the development of their solutions for unmet medical needs," commented Robert Lucia, CEO of MATWIN.
*Maturation & Accelerating Translation With INdustry
About MATWIN
"Maturation & Accelerating Translation With Industry" is a nationwide support program intended for innovative projects in oncology at an early stage. It is based on a public-private partnership between twelve pharmaceutical companies focusing on oncology (Amgen, AstraZeneca, BayerHealthCare, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi) and the French Cancéropôles network. Since June 2015, MATWIN has become a subsidiary of the UNICANCER Group, which brings together the 20 French Comprehensive Cancer Centers.
MATWIN's main objectives are to:
· identify and select innovative cancer research projects with strong transfer potential; · support these projects and help the teams to better structure projects answering market needs; · increase the best projects' industrial exposure to boost their development, for the benefit of the patients.
For more information, please visit www.matwin.fr and follow us social networks (Twitter @MATWIN Bdx)
About Pierre Fabre Fund for Innovation
Pierre Fabre Fund for Innovation is a unique Open Innovation initiative, launched in November 2015 by Pierre Fabre Laboratories. Pierre Fabre Fund for Innovation is intended for biotech companies, startups and research laboratories (public or private) specializing in oncology or dermatology, two of the core therapeutic activities of Pierre Fabre R&D.
Pierre Fabre Fund for Innovation supports R&D projects either within 24 months from reaching clinical development or at early stage of clinical development. Pierre Fabre Fund for Innovation offers diverse forms of collaboration: sharing Pierre Fabre's expertise over the full pharmaceutical value chain, co-financing of the research program, taking minority equity participation or negotiating license agreements. The combination of diverse forms of support is also conceivable. Pierre Fabre's support on the long term will be conditioned to the reaching of key milestones in the innovation process.
Open to all international partnership opportunity, the main goal for Pierre Fabre Fund for Innovation is to help innovative companies located in France or in Europe, at a time when many European biotech companies, startups and research laboratories often lack the internal capabilities expertise to move on from discovery to proof of concept, or lack financial resources to turn their projects into reality. Pierre Fabre's expertise and capabilities made available to its future partners include pharmacology, new chemical entities, biotherapies, immunotherapy, translational medicine, preclinical and clinical development, production of clinical batches, market access as well as market and regulatory strategy.
Pierre Fabre Fund for Innovation will be led by a Steering Committee comprised of Bertrand Parmentier, Group CEO, Frédéric Duchesne, Pharmaceuticals CEO, Luc Péligry, Group CFO, Frédéric Desdouits, Business Development Director and Laurent Audoly, Pharmaceuticals R&D Director. Laurent Audoly, as the Project Managing Partner, will take the lead of the operational management of the program. This deliberately restricted and executive governance will ensure quick and customized feedbacks to applicants.
Pierre Fabre Fund for Innovation is part of a genuine co-development approach. We are willing to share the risks and benefits associated with the development of products at an early stage, as part of a win/win partnership between the applicant, current or future investors, and the Pierre Fabre Group, which brings its expertise in pharmaceutical development.
About Pierre Fabre
Pierre Fabre is a private pharmaceuticals and dermo-cosmetics company founded in 1962 by Mr. Pierre Fabre. Its turnover reached over 2.2 billion Euros* in 2015, spread over 130 countries. The company is structured around two divisions: Pharmaceuticals (prescription drugs, consumer health care) and Dermo-cosmetics (including the Europe and Asia market-leader brand Eau Thermale Avène). Pierre Fabre employs some 11,000 people worldwide and owns subsidiaries in 43 countries. In 2015, the company allocated 16% of its pharmaceuticals sales to R&D with a focus on 4 therapeutic areas: oncology, dermatology, CNS and consumer health care.
Pierre Fabre Laboratories have always developed durable and valuable scientific partnerships with innovators from public research institutions (CRNS, Inserm...), faculties and universities (Ecole Polytechnique de Lausanne, Université de Saclay...), international pharmaceutical laboratories (Allergan, Abbvie, Maruho...) and biotech companies (Array, BioPharma, AbCheck, Cellectar...).
Through the Group's controlling company Pierre Fabre Participations, Pierre Fabre is 86% owned by the Pierre Fabre Foundation, a recognized public-interest organization since 1999. Up to 8% of the remaining shares are held by the company's employees and the remaining balance is held as treasury stock.
To find out more about Pierre Fabre, please go to www.pierre-fabre.com
Created and hosted by MATWIN, the MEET2WIN Business Convention, which is entirely dedicated to open innovation and collaborative research in oncology, will be held on May 12th and 13th in Bordeaux, France. More than 200 participants involved in the oncology innovation cycle (large groups, biotech companies, startups, as well as project initiators, researchers and fundraisers) are expected to attend, meet and forge new collaborations.
A partner of MATWIN since 2014, the Pierre Fabre Group will expand its contribution to this year's MEET2WIN Convention. As such, several high potential research projects in oncology and onco-dermatology that have been pre-selected by MATWIN will be evaluated by the Pierre Fabre Fund for Innovation. If selected and a partnership signed, these projects will benefit from the support and expertise of the Pierre Fabre Group across the spectrum of R&D activites and/orfrom financial support for their project in order to advance through the clinic and to significant value inflexion points. The MEET2WIN Convention will offer project bearers, pre-selected by MATWIN, an opportunity to meet executives from Pierre Fabre Fund for Innovation and submit their applications directly to them.
"Biotech entrepreneurs in oncology and onco-dermatology can expect a highly collaborative interaction with us in order to advance projects in the most efficient manner across the product development steps.. This collaboration between MATWIN and Pierre Fabre Fund for Innovation falls into Pierre Fabre Pharmaceuticals' R&D strategy to forge partnerships with external parties showing a real potential for delivering highly differentiated medicines to patients," said Laurent Audoly, Head of R&D Pierre Fabre Pharmaceuticals and Managing Partner of the Pierre Fabre Fund for Innovation.
"We want to offer true flexibility to our partners, without forcing them to follow a set pattern. We are willing to take risks on projects that are still at a very early stage of the innovation process. The whole purpose of strengthening our ties with MATWIN is to identify projects of interest," said Vincent Serra, Operating Manager of the Pierre Fabre Fund for Innovation.
"This new partnership with Pierre Fabre Fund for Innovation offers additional opportunities for project applications to MATWIN. It will expand the expertise and support we provide at an early stage, allowing the most promising projects to boost the development of their solutions for unmet medical needs," commented Robert Lucia, CEO of MATWIN.
*Maturation & Accelerating Translation With INdustry
About MATWIN
"Maturation & Accelerating Translation With Industry" is a nationwide support program intended for innovative projects in oncology at an early stage. It is based on a public-private partnership between twelve pharmaceutical companies focusing on oncology (Amgen, AstraZeneca, BayerHealthCare, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi) and the French Cancéropôles network. Since June 2015, MATWIN has become a subsidiary of the UNICANCER Group, which brings together the 20 French Comprehensive Cancer Centers.
MATWIN's main objectives are to:
· identify and select innovative cancer research projects with strong transfer potential; · support these projects and help the teams to better structure projects answering market needs; · increase the best projects' industrial exposure to boost their development, for the benefit of the patients.
For more information, please visit www.matwin.fr and follow us social networks (Twitter @MATWIN Bdx)
About Pierre Fabre Fund for Innovation
Pierre Fabre Fund for Innovation is a unique Open Innovation initiative, launched in November 2015 by Pierre Fabre Laboratories. Pierre Fabre Fund for Innovation is intended for biotech companies, startups and research laboratories (public or private) specializing in oncology or dermatology, two of the core therapeutic activities of Pierre Fabre R&D.
Pierre Fabre Fund for Innovation supports R&D projects either within 24 months from reaching clinical development or at early stage of clinical development. Pierre Fabre Fund for Innovation offers diverse forms of collaboration: sharing Pierre Fabre's expertise over the full pharmaceutical value chain, co-financing of the research program, taking minority equity participation or negotiating license agreements. The combination of diverse forms of support is also conceivable. Pierre Fabre's support on the long term will be conditioned to the reaching of key milestones in the innovation process.
Open to all international partnership opportunity, the main goal for Pierre Fabre Fund for Innovation is to help innovative companies located in France or in Europe, at a time when many European biotech companies, startups and research laboratories often lack the internal capabilities expertise to move on from discovery to proof of concept, or lack financial resources to turn their projects into reality. Pierre Fabre's expertise and capabilities made available to its future partners include pharmacology, new chemical entities, biotherapies, immunotherapy, translational medicine, preclinical and clinical development, production of clinical batches, market access as well as market and regulatory strategy.
Pierre Fabre Fund for Innovation will be led by a Steering Committee comprised of Bertrand Parmentier, Group CEO, Frédéric Duchesne, Pharmaceuticals CEO, Luc Péligry, Group CFO, Frédéric Desdouits, Business Development Director and Laurent Audoly, Pharmaceuticals R&D Director. Laurent Audoly, as the Project Managing Partner, will take the lead of the operational management of the program. This deliberately restricted and executive governance will ensure quick and customized feedbacks to applicants.
Pierre Fabre Fund for Innovation is part of a genuine co-development approach. We are willing to share the risks and benefits associated with the development of products at an early stage, as part of a win/win partnership between the applicant, current or future investors, and the Pierre Fabre Group, which brings its expertise in pharmaceutical development.
About Pierre Fabre
Pierre Fabre is a private pharmaceuticals and dermo-cosmetics company founded in 1962 by Mr. Pierre Fabre. Its turnover reached over 2.2 billion Euros* in 2015, spread over 130 countries. The company is structured around two divisions: Pharmaceuticals (prescription drugs, consumer health care) and Dermo-cosmetics (including the Europe and Asia market-leader brand Eau Thermale Avène). Pierre Fabre employs some 11,000 people worldwide and owns subsidiaries in 43 countries. In 2015, the company allocated 16% of its pharmaceuticals sales to R&D with a focus on 4 therapeutic areas: oncology, dermatology, CNS and consumer health care.
Pierre Fabre Laboratories have always developed durable and valuable scientific partnerships with innovators from public research institutions (CRNS, Inserm...), faculties and universities (Ecole Polytechnique de Lausanne, Université de Saclay...), international pharmaceutical laboratories (Allergan, Abbvie, Maruho...) and biotech companies (Array, BioPharma, AbCheck, Cellectar...).
Through the Group's controlling company Pierre Fabre Participations, Pierre Fabre is 86% owned by the Pierre Fabre Foundation, a recognized public-interest organization since 1999. Up to 8% of the remaining shares are held by the company's employees and the remaining balance is held as treasury stock.
To find out more about Pierre Fabre, please go to www.pierre-fabre.com
